EZH2 in normal hematopoiesis and hematological malignancies

被引：86

作者：

Herviou, Laurie ^{[2
]}

Cavalli, Giacomo ^{[2
]}

Cartron, Guillaume ^{[3
,4
]}

Klein, Bernard ^{[1
,2
,3
]}

Moreaux, Jerome ^{[1
,2
,3
]}

机构：

[1] CHU Montpellier, Dept Biol Hematol, Montpellier, France

[2] CNRS, Inst Human Genet, UPR1142, Montpellier, France

[3] Univ Montpellier I, UFR Med, Montpellier, France

[4] CHU Montpellier, Dept Clin Hematol, Montpellier, France

来源：

ONCOTARGET | 2016年 / 7卷 / 03期

关键词：

hematological malignancies; EZH2; Polycomb complex; therapeutic target; HISTONE METHYLTRANSFERASE EZH2; POLYCOMB-GROUP GENE; GROUP PROTEIN EZH2; B-CELL LYMPHOMAS; AGGRESSIVE BREAST-CANCER; REPRESSIVE COMPLEX 2; GERMINAL-CENTER; SOMATIC MUTATIONS; STEM-CELLS; SELECTIVE-INHIBITION;

D O I：

10.18632/oncotarget.6198

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, inhibits gene expression through methylation on lysine 27 of histone H3. EZH2 regulates normal hematopoietic stem cell self-renewal and differentiation. EZH2 also controls normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. Specific small molecules have been recently developed to exploit the oncogenic addiction of tumor cells to EZH2. Their therapeutic potential is currently under evaluation. This review summarizes the roles of EZH2 in normal and pathologic hematological processes and recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies.

引用

页码：2284 / 2296

页数：13

共 101 条

[91] H3.3 replacement facilitates epigenetic reprogramming of donor nuclei in somatic cell nuclear transfer embryos [J].

Wen, Duancheng ;

Banaszynski, Laura A. ;

Rosenwaks, Zev ;

Allis, C. David ;

Rafii, Shahin .

NUCLEUS-AUSTIN, 2014, 5 (05) :369-375

[92] CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin [J].

Weth, Oliver ;

Paprotka, Christine ;

Guenther, Katharina ;

Schulte, Astrid ;

Baierl, Manuel ;

Leers, Joerg ;

Galjart, Niels ;

Renkawitz, Rainer .

NUCLEIC ACIDS RESEARCH, 2014, 42 (19) :11941-11951

[93] Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner [J].

Xie, Huafeng ;

Xu, Jian ;

Hsu, Jessie H. ;

Minh Nguyen ;

Fujiwara, Yuko ;

Peng, Cong ;

Orkin, Stuart H. .

CELL STEM CELL, 2014, 14 (01) :68-80

[94] Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring [J].

Xu, Feng ;

Li, Xiao ;

Wu, Lingyun ;

Zhang, Qingxia ;

Yang, Rui ;

Yang, Yujuan ;

Zhang, Zheng ;

He, Qi ;

Chang, Chunkang .

ANNALS OF HEMATOLOGY, 2011, 90 (06) :643-653

[95] EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent [J].

Xu, Kexin ;

Wu, Zhenhua Jeremy ;

Groner, Anna C. ;

He, Housheng Hansen ;

Cai, Changmeng ;

Lis, Rosina T. ;

Wu, Xiaoqiu ;

Stack, Edward C. ;

Loda, Massimo ;

Liu, Tao ;

Xu, Han ;

Cato, Laura ;

Thornton, James E. ;

Gregory, Richard I. ;

Morrissey, Colm ;

Vessella, Robert L. ;

Montironi, Rodolfo ;

Magi-Galluzzi, Cristina ;

Kantoff, Philip W. ;

Balk, Steven P. ;

Liu, X. Shirley ;

Brown, Myles .

SCIENCE, 2012, 338 (6113) :1465-1469

[96] EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity [J].

Yan, Junli ;

Ng, Siok-Bian ;

Tay, Jim Liang-Seah ;

Lin, Baohong ;

Koh, Tze Loong ;

Tan, Joy ;

Selvarajan, Viknesvaran ;

Liu, Shaw-Cheng ;

Bi, Chonglei ;

Wang, Shi ;

Choo, Shoa-Nian ;

Shimizu, Norio ;

Huang, Gaofeng ;

Yu, Qiang ;

Chng, Wee-Joo .

BLOOD, 2013, 121 (22) :4512-4520

[97] Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells [J].

Zhan, FH ;

Hardin, J ;

Kordsmeier, B ;

Bumm, K ;

Zheng, MZ ;

Tian, EM ;

Sanderson, R ;

Yang, Y ;

Wilson, C ;

Zangari, M ;

Anaissie, E ;

Morris, C ;

Muwalla, F ;

van Rhee, F ;

Fassas, A ;

Crowley, J ;

Tricot, G ;

Barlogie, B ;

Shaughnessy, J .

BLOOD, 2002, 99 (05) :1745-1757

[98] RETRACTED: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas (Retracted article. See vol. 41, pg. 1198, 2023) [J].

Zhang, Xinwei ;

Zhao, Xiaohong ;

Fiskus, Warren ;

Lin, Jianhong ;

Lwin, Tint ;

Rao, Rekha ;

Zhang, Yizhuo ;

Chan, John C. ;

Fu, Kai ;

Marquez, Victor E. ;

Chen-Kiang, Selina ;

Moscinski, Lynn C. ;

Seto, Edward ;

Dalton, William S. ;

Wright, Kenneth L. ;

Sotomayor, Eduardo ;

Bhalla, Kapil ;

Tao, Jianguo .

CANCER CELL, 2012, 22 (04) :506-523

[99] Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells [J].

Zhao, Fei ;

Chen, Yan ;

Zeng, Linglan ;

Li, Rui ;

Zeng, Rong ;

Wen, Lu ;

Liu, Yuan ;

Zhang, Chun .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 646 (1-3) :1-11

[100] Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro [J].

Zhao, Fei ;

Chen, Yan ;

Li, Rui ;

Liu, Yuan ;

Wen, Lu ;

Zhang, Chun .

TOXICOLOGY, 2010, 267 (1-3) :70-79

← 2 3 4 5 6 7 8 9 10 11 →